ANI PHARMACEUTICALS INC — Form 8-K
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
ANI Pharmaceuticals reported Q2 2026 total net revenues of $266.0M (+25.9% YoY), with Cortrophin Gel net revenues reaching $117.1M (+43.5% YoY). The company expanded its Rare Disease sales force by ~50% (from ~120 to ~180 reps) to enter the acute gouty arthritis market, targeting ~285,000 addressable patients. ANI reaffirmed full-year 2026 guidance of $1,080–$1,140M total revenue and $285–$300M adjusted non-GAAP EBITDA, but modestly lowered Cortrophin Gel guidance to $520–$540M (from $540–$575M), reflecting 50–55% full-year growth. The company also authorized a $100M share repurchase program through May 2029 and generated $115M operating cash flow year-to-date.
Why this rating
Strong Q2 execution (+26% revenue, +32% EBITDA) and successful gout expansion (95%+ reps generating cases, 1/3 prescribers multi-case) drive meaningful growth. Cortrophin Gel guidance lower but still robust (50–55%). At $1.3B market cap, $1.1B revenue + gout upside is material. Execution risk remains on new market penetration.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.